Focus: GE HealthCare is a diagnostic imaging and nuclear medicine company with 714 active job openings, operating across medical devices, contrast agents, and radiopharmaceuticals. The company maintains a portfolio spanning X-ray contrast media, nuclear imaging agents, and advanced imaging modalities.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Hot — 2108 jobs added in 30d
Net +1420 (2108 new, 688 removed). Aggressive expansion phase.
Strong career optionality for engineers and commercial professionals seeking growth in diagnostic imaging; weak choice for pharma scientists expecting robust early-stage drug pipelines.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Legacy contrast agent for urinary bladder imaging; approaching loss of exclusivity with limited clinical differentiation.
Help build intelligence for GE HealthCare
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GE HealthCare's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Established iohexol formulation for X-ray contrast; mature product with approaching patent expiry and generic competition risk.
Kit-based radiopharmaceutical with limited data; approaching loss of exclusivity.
Established nuclear tracer; approaching end of market exclusivity in competitive diagnostic imaging landscape.
High-concentration iohexol formulation; mature product facing LOE and generic pressure.
Radiopharmaceutical kit with approaching loss of exclusivity.
Chelated imaging agent; mature product approaching patent cliff.
Lower-concentration iohexol formulation; LOE approaching with limited growth prospects.
Radiopharmaceutical kit approaching end of market exclusivity.
Very low-concentration iohexol; niche formulation with approaching LOE.
46 discontinued, 14 duplicate formulations not shown
GE HealthCare Gains FDA Clearance for AI Radiation Planning Software - Yahoo Finance
GE HealthCare Gains FDA Clearance for AI Radiation Planning Software Yahoo Finance
GE HealthCare to Showcase Latest Technologies, AI-enabled Workflows - Imaging Technology News
GE HealthCare to Showcase Latest Technologies, AI-enabled Workflows Imaging Technology News
GE HealthCare’s AI-Driven Adaptive Theranostics Push Might Change The Case For Investing In GEHC - Sahm
GE HealthCare’s AI-Driven Adaptive Theranostics Push Might Change The Case For Investing In GEHC Sahm
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations - Business Wire
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations Business Wire
EQS-News: FAMAR Group announces contract manufacturing agreement with GE HealthCare - boerse.de - boerse.de
EQS-News: FAMAR Group announces contract manufacturing agreement with GE HealthCare - boerse.de boerse.de
Peter Arduini: Susquehanna Marketer, GE Healthcare Alumnus, and President and CEO of GE HealthCare - BBN Times
Peter Arduini: Susquehanna Marketer, GE Healthcare Alumnus, and President and CEO of GE HealthCare BBN Times
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo